Yuzbasioglu, Mebrure Burcak; Eskazan, Ahmet Emre published an article in 2021, the title of the article was Bosutinib – related pleural effusion in patients with chronic myeloid leukemia.HPLC of Formula: 380843-75-4 And the article contains the following content:
A review. Tyrosine kinase inhibitors (TKIs) are the mainstay of the current management of chronic myeloid leukemia (CML). Dasatinib is a 2GTKI, which is utilized in CML treatment both in the upfront and salvage settings Lymphocytosis pleural effusion. Bosutinib is another potent 2GTKI, which can also be used in the first- and subsequent-lines in patients with CML [20]. It is a dual Src/Abl TKI, and it exhibits minimal inhibitory activity against c-KIT or PDGFR [21]. Diarrhea is the most common AE of bosutinib therapy. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).HPLC of Formula: 380843-75-4
The Article related to review dasatinib bosutinib anticancer agent chronic myeloid leukemia, adverse event, bosutinib, chronic myeloid leukemia, pleural effusion, tyrosine kinase inhibitor, Pharmacology: Reviews and other aspects.HPLC of Formula: 380843-75-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics